Vestas receives new order in the US

Fair breezes blowing in Colorado for Danish wind giant

Danish wind turbine manufacturer Vestas has received an order for 80 wind turbines to be built in its factories in Colorado.

The 160 megawatt (MW) order comes from one of the company’s longstanding customers – EDF Energies Nouvelles / EDF Renewable Energy – and will involve the construction of 80 2.0 MW wind turbines.

The agreement will run between 2016 and 2019 and includes wind projects in Europe and the US.

READ MORE: Vestas inks big US order

“Since we signed our first major supply agreement with Vestas in 2013, EDF RE has installed more than two gigawatts’ worth of Vestas turbines in the US,” said Tristan Grimbert, the managing director of EDF Renewable Energy.

In addition to construction, Vestas also has an agreement to service the wind park in order to optimise its energy production.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.